SCILEX Pharmaceuticals Builds Out Market Access Team
Jun 22, 2015, 04:16 ET
MALVERN, Pa., June 22, 2015 /PRNewswire/ -- SCILEX Pharmaceuticals, Inc., a company engaged in the development and commercialization of products focused on the treatment of pain, today announced the appointment of three key executives to its Market Access Team. These appointments include Ms. Michele Pericci as Director of Business Analytics and Contracting, Mr. Thom Brough as Director of Trade & Distribution, and Mr. Jay Krippes as Executive Director of Managed Markets. Each of these pharmaceutical executives bring more than 30 years of industry experience to SCILEX. They will join SCILEX's recently appointed Director of Payer Advocacy and Government Affairs, Ms. Jessica Wolfe, and the team will report to Mr. Bill Stewart, the company's Vice President of Market Access and Commercial Development.
This team will help to bolster SCILEX's proprietary drug program, which develops and commercializes late-stage pharmaceutical products focused on the treatment of pain, including ZTlido™ (lidocaine patch 1.8%) a next-generation patch being developed to treat postherpetic neuralgia, or after-shingles pain.
The Market Access Team will ensure SCILEX Pharmaceuticals strikes the ideal balance in its development and commercialization decisions as the company prepares for the potential commercialization of its products.
"We are delighted to secure this depth and breadth of industry expertise to enhance our Market Access Team. This group will be instrumental in our growth plans as we assess the commercialization potential of a range of products to treat pain," said Anthony Mack, Chief Executive Officer of SCILEX.
Mr. Brough has extensive background in new product launches, distribution, project management and pricing implementation. He has a proven track record as Director of Trade & Distribution at Iroko Pharmaceuticals and Avanir Pharmaceuticals, and has worked as an independent pharmaceutical trade consultant. His other roles include Senior Director of Trade Relations at CollaGenex Pharmaceuticals, Trade Relations Manager at AMGEN, and District Sales Manager at Key Pharmaceuticals. Mr. Brough earned a Master of Education and a Bachelor of Science degree from Bowling Green State University.
Ms. Pericci is an expert in healthcare business evaluation and was most recently President of PBEAR, a consulting firm specializing in analytics research, managed markets and remote healthcare solutions. Previously she held management positions at companies including Novartis Pharmaceuticals and Shionogi Inc. She holds an M.B.A. in Pharmaceutical Studies and an M.B.A. in Marketing from Fairleigh Dickinson University and a B.A. in Sociology and Psychology from Wilkes University.
Mr. Krippes specializes in managed markets and business development throughout the U.S. He has worked for companies that include Stotle, Iroko Pharmaceuticals, Arca Biopharma, Collagenex Pharmaceuticals, Lederle Laboratories and Boehringer Mannheim Therapeutics. Mr. Krippes received his Bachelor of Arts degree from the University of California, Los Angeles.
About SCILEX Pharmaceuticals
SCILEX Pharmaceuticals, Inc., located in Malvern, PA, is an emerging specialty pharmaceutical company engaged in the development and commercialization of late-stage pharmaceutical products focused on the treatment of pain. The Company's vision is to become a world-class, global pharmaceutical company that delivers the next generation of innovative products. Leveraging its network of global relationships, the Company seeks to acquire high barrier-to-entry, late-stage products for development and commercialization. The Company's first product under development, ZTlido™ (lidocaine patch 1.8%), is a next-generation branded lidocaine patch formulation for the potential treatment of relieving the pain of postherpetic neuralgia, also referred to as after-shingles pain. For more information visit www.scilexpharma.com
ZTlido™ is a trademark owned by SCILEX Pharmaceuticals, Inc. Any other trademarks are the property of their respective owners. A proprietary name review by the FDA is planned. © 2015 SCILEX Pharmaceuticals, Inc. All Rights Reserved.
For more information contact:
SCILEX Pharmaceuticals, Inc.
MBS Value Partners, LLC
SOURCE SCILEX Pharmaceuticals, Inc.
Share this article